Theravance Biopharma (TBPH) Other Accumulated Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Other Accumulated Expenses data on file, last reported at $988000.0 in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 52.29% year-over-year to $988000.0 in Q1 2026; TTM through Mar 2026 was $988000.0, a 52.29% decrease from a year earlier, with the FY2025 full-year figure at $1.5 million, down 32.93% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $988000.0, down from $1.5 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for TBPH reached as high as $2.3 million in Q2 2022 and fell as low as $142000.0 in Q3 2022.
• Historically, Other Accumulated Expenses has averaged $1.4 million across 5 years, with a median of $1.3 million in 2025.
• Across the five-year window, Other Accumulated Expenses slumped 92.24% in 2022 and jumped 963.38% in 2023, its largest moves.
• Year by year, Other Accumulated Expenses stood at $1.1 million in 2022, then advanced by 8.67% to $1.2 million in 2023, then surged by 78.4% to $2.2 million in 2024, then slumped by 32.93% to $1.5 million in 2025, then plunged by 33.47% to $988000.0 in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $988000.0 in Q1 2026, $1.5 million in Q4 2025, and $1.3 million in Q3 2025.